Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4279711
Max Phase: Preclinical
Molecular Formula: C30H37N5O4
Molecular Weight: 531.66
Molecule Type: Small molecule
Associated Items:
ID: ALA4279711
Max Phase: Preclinical
Molecular Formula: C30H37N5O4
Molecular Weight: 531.66
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C(C)[C@@H]1CC=C(Cn2cc(COc3cc(C4NC(=O)NC5=C4C(=O)CC(C)(C)C5)ccc3OC)nn2)CC1
Standard InChI: InChI=1S/C30H37N5O4/c1-18(2)20-8-6-19(7-9-20)15-35-16-22(33-34-35)17-39-26-12-21(10-11-25(26)38-5)28-27-23(31-29(37)32-28)13-30(3,4)14-24(27)36/h6,10-12,16,20,28H,1,7-9,13-15,17H2,2-5H3,(H2,31,32,37)/t20-,28?/m1/s1
Standard InChI Key: MAIFGLFPWGOWLR-HFLPEKOISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 531.66 | Molecular Weight (Monoisotopic): 531.2846 | AlogP: 5.17 | #Rotatable Bonds: 8 |
Polar Surface Area: 107.37 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.52 | CX Basic pKa: | CX LogP: 3.73 | CX LogD: 3.73 |
Aromatic Rings: 2 | Heavy Atoms: 39 | QED Weighted: 0.46 | Np Likeness Score: -0.46 |
1. Vendrusculo V, de Souza VP, M Fontoura LA, M D'Oca MG, Banzato TP, Monteiro PA, Pilli RA, de Carvalho JE, Russowsky D.. (2018) Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity., 9 (9): [PMID:30288229] [10.1039/C8MD00270C] |
Source(1):